SG10201907026RA - Prevention or Treatment of Uratic or Gouty Diseases - Google Patents
Prevention or Treatment of Uratic or Gouty DiseasesInfo
- Publication number
- SG10201907026RA SG10201907026RA SG10201907026RA SG10201907026RA SG10201907026RA SG 10201907026R A SG10201907026R A SG 10201907026RA SG 10201907026R A SG10201907026R A SG 10201907026RA SG 10201907026R A SG10201907026R A SG 10201907026RA SG 10201907026R A SG10201907026R A SG 10201907026RA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- gout
- uric acid
- uratic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides uses of the compounds represented by formula (I), pharmaceutically acceptable salts, solvates thereof or a pharmaceutical composition comprising any one of them for lowering uric acid, anti-inflammation, preventing or treating uric acid or gout diseases, especially uses in the preparation of medicaments for the treatment or prevention of hyperuricemia, gout, gout inflammation, pain, and uric acid nephropathy. (In formula (I), R is selected from hydrogen or CI-4 alkyl and so on, R2 is selected from CI-10 alkyl and so on, and R3 is selected from halogen atoms and so on.) 74
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510048096 | 2015-01-30 | ||
CN201510080714 | 2015-02-13 | ||
CN201510079809 | 2015-02-13 | ||
CN201510216089 | 2015-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201907026RA true SG10201907026RA (en) | 2019-09-27 |
Family
ID=56542370
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907026RA SG10201907026RA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
SG11201705889VA SG11201705889VA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705889VA SG11201705889VA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
Country Status (26)
Country | Link |
---|---|
US (1) | US10322132B2 (en) |
EP (1) | EP3251675B1 (en) |
JP (1) | JP6678685B2 (en) |
KR (1) | KR102128810B1 (en) |
CN (1) | CN107206002B (en) |
AU (1) | AU2016212625B2 (en) |
BR (1) | BR112017016065A2 (en) |
CA (1) | CA2973746C (en) |
CY (1) | CY1124383T1 (en) |
DK (1) | DK3251675T3 (en) |
EA (1) | EA034139B1 (en) |
ES (1) | ES2881872T3 (en) |
HK (2) | HK1244434A1 (en) |
HR (1) | HRP20211007T1 (en) |
HU (1) | HUE054741T2 (en) |
IL (1) | IL253726B2 (en) |
LT (1) | LT3251675T (en) |
MA (1) | MA41431B1 (en) |
MX (1) | MX2017009853A (en) |
PL (1) | PL3251675T3 (en) |
PT (1) | PT3251675T (en) |
SG (2) | SG10201907026RA (en) |
SI (1) | SI3251675T1 (en) |
TW (1) | TWI680761B (en) |
WO (1) | WO2016119570A1 (en) |
ZA (1) | ZA201704600B (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
WO1993016699A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
AR015966A1 (en) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT |
EP1781657B1 (en) * | 2004-02-14 | 2013-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Medicaments with hm74a receptor activity |
BRPI0713561A2 (en) * | 2006-06-23 | 2012-03-13 | Incyte Corporation | compound or a pharmaceutically acceptable salt or prodrug thereof, composition, and methods of modulating the receptor and treating a disease |
WO2007150026A2 (en) * | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/en active IP Right Grant
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/en active Active
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 SI SI201631264T patent/SI3251675T1/en unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/en not_active Application Discontinuation
- 2016-01-28 MX MX2017009853A patent/MX2017009853A/en unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/en unknown
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 MA MA41431A patent/MA41431B1/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/en unknown
- 2016-01-28 ES ES16742632T patent/ES2881872T3/en active Active
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/en active
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 PT PT167426329T patent/PT3251675T/en unknown
- 2016-01-28 EA EA201791714A patent/EA034139B1/en unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/en active Application Filing
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/en active Active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/en unknown
- 2016-01-29 TW TW105102935A patent/TWI680761B/en active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2018
- 2018-03-21 HK HK18103914.7A patent/HK1244434A1/en unknown
- 2018-04-16 HK HK18104884.1A patent/HK1245146A1/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/en unknown
- 2021-06-26 HR HRP20211007TT patent/HRP20211007T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
MX2020001776A (en) | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP<sub>3</sub> INHIBITORS. | |
MX2021013075A (en) | Oxysterols and methods of use thereof. | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
MX2020011449A (en) | Oxysterols and methods of use thereof. | |
MX2018005890A (en) | Compositions for treating spinal muscular atrophy. | |
MX2019003143A (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof. | |
PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2016001400A (en) | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2016015248A (en) | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy. | |
PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
MX2018005041A (en) | Compounds for treating amyotrophic lateral sclerosis. | |
GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
SA519402103B1 (en) | 1, 6- Naphthyridine as CDK4/6 Inhibitor | |
MX2019006721A (en) | Treatment for primary biliary cholangitis. | |
JO3789B1 (en) | Compositions and therapeutic methods for the treatment of complement -associated diseases | |
NZ741318A (en) | Compound for treating or preventing hyperuricemia or gout | |
EA033237B1 (en) | New pyrazolopyrimidine derivatives as nik inhibitors, pharmaceutical composition and medicament comprising same | |
MX2020001531A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors. | |
SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
MX2017000208A (en) | Quinolizinone derivatives as pi3k inhibitors. | |
SA519410865B1 (en) | Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof |